The paper "Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options" is a broad review of medication treatment for adult anxiety disorders, focused on panic disorder, generalized anxiety disorder, social anxiety disorder, and specific phobias. It does not cover PTSD or OCD. Its two main goals are to summarize currently used medications, including both approved and off-label options, and to assess newer drug classes being investigated.
The review’s core conclusion is that SSRIs and SNRIs remain the main first-line medication treatments for panic disorder, generalized anxiety disorder, and social anxiety disorder. The authors describe them as effective and generally well tolerated, while noting familiar drawbacks such as nausea, headache, GI side effects, and especially sexual dysfunction. They also note that older antidepressants such as tricyclics and MAOIs can work, but are used less often because of side-effect burden, overdose risk, and dietary restrictions.
Beyond SSRIs and SNRIs, the paper reviews a wide range of commonly used alternatives and adjuncts. These include buspirone, which is FDA-approved for anxiety and used especially in GAD; benzodiazepines, which remain effective but are no longer favored as first-line monotherapy because of concerns about dependence, misuse, falls, and prescribing patterns; and other off-label options such as mirtazapine, hydroxyzine, propranolol, clonidine, pregabalin, gabapentin, and some antipsychotics. The review presents these as part of real-world anxiety pharmacotherapy, but not as clear replacements for first-line serotonergic agents.
A major theme of the article is that the pipeline for new anxiety medications has been relatively weak. The authors say there have been few drugs developed specifically for anxiety disorders, and that many newer studies suffer from poor design, including limited controls and too few head-to-head comparisons against established treatments like SSRIs or benzodiazepines. They also note a broader problem: despite multiple available treatments, a substantial minority of patients still have treatment-refractory anxiety.
For emerging therapies, the review discusses investigational approaches involving glutamate modulators, neuropeptides, neurosteroids, cannabinoids, and natural remedies. However, its overall assessment is cautious: randomized controlled evidence is limited, and many recent trials have been negative. The review specifically says that while some recent studies of agents such as ketamine, d-cycloserine, and cannabidiol have been conducted, results have mostly been disappointing, with only kava and PH94B, an inhaled neuroactive steroid, standing out as showing some promise.
Overall, the paper argues that current anxiety pharmacotherapy still depends heavily on established medication classes, especially SSRIs and SNRIs, while genuinely novel options remain underdeveloped. The authors’ bottom line is not that there are no promising new directions, but that the field needs larger, better-designed studies and more research into new biological pathways before emerging treatments can meaningfully change practice.
